Edwards Lifesciences Corp. Takeaways From Management Meetings

Goldman Sachs reiterates its Buy rating on Edwards Lifesciences following management meetings, citing confidence in 10%+ organic revenue growth and robust clinical catalysts in 2H26.

Key Takeaways

• 1.Edwards is positioned for 10%+ organic revenue growth and sustained earnings leverage.
• 2.TAVR remains a central focus, with growth driven by disease awareness, asymptomatic opportunities, moderate AS, and valve-in-valve.
• 3.The company is expanding into surgical appendage management (LAAC) with potential to grow the category.

Table of Contents

• Valuation & Risks
• Disclosure Appendix

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial